Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

This is the protocol for a review and there is no abstract. The objectives are as follows: To investigate the effects of non-monthly versus monthly intravitreal injection of an anti-VEGF agent on best-corrected visual acuity (BCVA) in people with newly diagnosed nAMD at one-year follow-up

Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

Age-related macular degeneration (AMD) is one of the leading causes of permanent blindness worldwide. The current mainstay of treatment for neovascular AMD (nAMD) is intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents: aflibercept, ranibizumab, and off-label bevacizumab. Injections can be given monthly, every two or three months ('extended-fixed'), or as needed (pro re nata (PRN)). A variant of PRN is 'treat-and-extend' whereby injections are resumed if recurrence is detected and then delivered with increasing intervals. Currently, injection frequency varies among practitioners, which underscores the need to characterize an optimized approach to nAMD management